FOLD - Amicus Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

FOLD is currently covered by 10 analysts with an average price target of $12.89. This is a potential upside of $5.54 (75.37%) from yesterday's end of day stock price of $7.35.

Amicus Therapeutics's activity chart (see below) currently has 106 price targets and 93 ratings on display. The stock rating distribution of FOLD is 83.33% BUY and 16.67% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 47.53% with an average time for these price targets to be met of 354.71 days.

Highest price target for FOLD is $21, Lowest price target is $12, average price target is $16.4.

Most recent stock forecast was given by KRISTEN KLUSKA from CANTOR FITZGERALD on 15-Jan-2025.

Currently out of the existing stock ratings of FOLD, 20 are a BUY (83.33%), 4 are a HOLD (16.67%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$21

$14.17 (207.47%)

$21

3 months 10 days ago
(15-Jan-2025)

0/7 (0%)

$11.73 (126.54%)

Buy

$12

$5.17 (75.70%)

$18

4 months 12 days ago
(13-Dec-2024)

0/4 (0%)

$2.64 (28.21%)

Buy

$17

$10.17 (148.90%)

$16

5 months 13 days ago
(12-Nov-2024)

6/15 (40%)

$6.51 (62.06%)

454

Buy

$15

$8.17 (119.62%)

$13

5 months 18 days ago
(07-Nov-2024)

2/4 (50%)

$4.02 (36.61%)

434

Buy

$15

$8.17 (119.62%)

$13

6 months 8 days ago
(17-Oct-2024)

2/9 (22.22%)

$3.03 (25.31%)

578

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is FOLD (Amicus Therapeutics) average time for price targets to be met?

On average it took 354.71 days on average for the stock forecasts to be realized with a an average price target met ratio 47.53

Which analyst has the current highest performing score on FOLD (Amicus Therapeutics) with a proven track record?

DEBJIT CHATTOPADHYAY

Which analyst has the most public recommendations on FOLD (Amicus Therapeutics)?

Debjit Chattopadhyay works at GUGGENHEIM and has 7 price targets and 3 ratings on FOLD

Which analyst is the currently most bullish on FOLD (Amicus Therapeutics)?

Michael Ulz with highest potential upside - $18.17

Which analyst is the currently most reserved on FOLD (Amicus Therapeutics)?

Gil Blum with lowest potential downside - -$0

Amicus Therapeutics in the News

Is Amicus Therapeutics, Inc. (FOLD) the Best Low Cost Stock to Buy According to Billionaires?

We recently published a list of 10 Best Low Cost Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Amicus Therapeutics, Inc. (NASDAQ:FOLD) stands against other best low cost stocks to buy according to billionaires. Markets are wobbling, and panic is becoming the headline. At times...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?